Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of severe diarrhea in the developed world. The vaccines decrease the risk of death among young children due to diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.
The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.
The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.
The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.
The global Rotavirus Vaccines market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Rotavirus Vaccines volume and value at global level, regional level and company level. From a global perspective, this report represents overall Rotavirus Vaccines market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Rotavirus Vaccines in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Rotavirus Vaccines manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Bharat Biotech
Merck & Co., Inc
GlaxoSmithKline plc
Lanzhou Institute of Biological
Bharat Biotech International Limited
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Segment by Application
Adult
Pediatric
The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.
The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.
The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.
The global Rotavirus Vaccines market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Rotavirus Vaccines volume and value at global level, regional level and company level. From a global perspective, this report represents overall Rotavirus Vaccines market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Rotavirus Vaccines in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Rotavirus Vaccines manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Bharat Biotech
Merck & Co., Inc
GlaxoSmithKline plc
Lanzhou Institute of Biological
Bharat Biotech International Limited
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Segment by Application
Adult
Pediatric
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
